All stock lists
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
Healthcare · Biotechnology
2.84+0.00 (+0.00%)
Insider Score
––Not scored
SABS Insider Score
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
SABS analyst forecast
Best analysts covering SABS
- Chardan Capital29%success rate · 17 calls
- HC Wainwright & Co.17%success rate · 18 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
SABS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Chardan Capital | Buy | — | — | Reiterated | 2026-06-17 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-06-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-12 |
| — | Rodman & Renshaw | Buy | — | — | Reiterated | 2026-05-11 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2026-03-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-10 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-12-18 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-11-17 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-09-19 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-08-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-07-22 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-05-15 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-04-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-29 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-01-29 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2024-11-07 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-09-12 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2024-09-09 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2024-08-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-12 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2024-05-21 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-21 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2024-04-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-04-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-04-02 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2024-04-02 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-01-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-11-14 |
| — | Ladenburg Thalmann | Neutral | — | — | Downgraded | 2023-10-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-06-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-06-16 |
| — | HC Wainwright& Co. | Buy | — | — | Reiterated | 2023-06-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-06-15 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2023-06-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-05-16 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2023-04-27 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-04-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-04-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-11-29 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2022-08-10 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2022-05-12 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2022-03-31 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2021-11-05 |
| — | Baird | Outperform | — | — | Reiterated | 2021-11-02 |
SABS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-09 | -0.16 | -0.46 | $100K | $0 |
| 2026-05-12 | -0.20 | -0.35 | $125K | $0 |
| 2026-08-06 | -0.28 | -0.28 | $125K | $0 |
| 2026-11-13 | -0.27 | 0.00 | $125K | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.